EVALUATION OF THE EFFICIENCY AND TOLERANCE OH THE CHIMIOTHERAPY REGORAFENIB IN 70 YEARS OLD AND MORE PATIENTS WITH A METASTATIC COLORECTAL CANCER

PHASE II STUDY EVALUATION OF EFFICACITY AND TOLERANCE OF REGORAFENIB FOR 70 YEARS OLD AND MORE PATIENTS WITH A METASTATIC COLORECTAL ADENOCARCIMA - REGOLD

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2015-002086-29-FR

Enrollment

Registered

2015-07-24

Start date

2015-09-04

Completion date

Unknown

Last updated

2020-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MedDRA version: 18.0 Level: PT Classification code 10061451 Term: Colorectal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Interventions

Trade Name: STIVARGA Pharmaceutical Form: Film-coated tablet INN or Proposed INN: REGORAFENIB CAS Number: 755037-03-7 Other descriptive name: REGORAFENIB Concentration unit: mg milligram(s) Concentrat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 42

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

France

Contacts

Public ContactPROJECT MANAGER

FEDERATION FRANCOPHONE DE CANCEROLOGIE DIGESTIVE

marie.moreau@u-bourgogne.fr33380393404

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 23, 2026